Publications by authors named "Lucas Vian"
Ther Adv Med Oncol
November 2024
Article Synopsis
- Recent advancements in antibody-drug conjugates (ADCs) have improved outcomes for patients with HER2-low-expressing breast cancer, a group that previously lacked effective targeted therapies.
- A systematic review and meta-analysis was conducted to evaluate the effectiveness of various ADCs, including trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), in treating HER2-low advanced or metastatic breast cancer, pulling data from multiple reputable sources.
- The findings revealed that patients treated with T-DXd had significantly better outcomes in terms of objective response rate, disease control rate, and overall survival compared to those receiving traditional treatment options, highlighting the potential of ADCs as effective therapies.
Cancer Treat Rev
August 2020
Article Synopsis
- HER2-positive breast cancer was identified in the 1980s and is known for its aggressive nature, but targeted therapies have significantly improved patient outcomes.
- Current treatment guidelines established in 2012 recommend a dual blockade of trastuzumab and pertuzumab as first-line therapy, with TDM-1 for second-line treatment, but options become limited in later lines.
- Recent trials have introduced new drugs like tucatinib, neratinib, and trastuzumab-deruxtecan, prompting reevaluation of treatment sequencing, particularly in patients who have already received TDM-1, while emerging biomarkers could further influence treatment choices and effectiveness in the future.
